Vitreous humor may serve as a useful alternative specimen for oxycodone analysis in death investigations where blood samples are not available or are of poor quality or limited quantity. The purpose of this study was to investigate the relationship between immunoassay results and gas chromatography-mass spectrometry (GC-MS) quantitation of oxycodone in postmortem vitreous humor and blood. When used with vitreous humor calibrators, the Microgenics DRI Oxycodone (EMIT) Assay was found to be linear from 25 to 500 ng/mL with an limit of detection of 25 ng/mL. Vitreous humor and postmortem blood precipitate immunoassay responses in 57 oxycodone-positive cases were found to be correlated (r 2 = 0.69, p < 0.01). Confirmation and quantitation of oxycodone in vitreous humor by GC-MS was linear from 50 to 1000 ng/mL with a limit of detection of 10 ng/mL and a limit of quantitation of 50 ng/mL. In 30 cases, oxycodone vitreous humor concentrations ranged from less than 50 to 945 ng/mL, and blood concentrations ranged from 103 to 768 ng/mL. The average vitreous humor/blood ratio was 1.16 and ranged from 0.12 to 3.26. Disparities between vitreous fluid and blood oxycodone concentrations were seen in a few cases.
Introduction
Vitreous humor is a useful alternative postmortem matrix for the detection of drugs and alcohol, particularly in death investigations where postmortem blood is not available or is of limited quality or quantity (1) . Located in a somewhat isolated compartment, vitreous fluid is often protected from trauma, bacterial invasion, and decomposition processes. This fluid is essentially a sterile saline solution with proteins present in low concentrations, resulting in a relatively stable environment for drugs and their metabolites during the postmortem interval (2) . Some of the drugs that have been previously studied in vitreous humor include cocaine (3) (4) (5) , opiates (5-7), benzodiazepines (8) , and phencyclidine (9) .
Drugs enter the vitreous humor by passive diffusion across the blood-vitreous barrier (1) , which is made up of ciliary epithelium, retinal pigment epithelium, and blood vessels of the retina (10) . Studies have shown that the concentrations of drugs in the vitreous humor display varying degrees of correlation with concentrations in the postmortem blood (3, 11) . In general, drugs that are highly protein-bound attain lower vitreous humor concentrations as only the free fraction can traverse the blood-vitreous barrier. Lipophilic drugs, such as benzodiazepines, tend to be found at higher concentrations in the blood than in vitreous fluid (8) .
Oxycodone is equipotent to morphine and is used clinically to treat moderate to severe pain. Hepatic cytochrome P450 enzymes metabolize oxycodone to noroxycodone, oxymorphone, and noroxymorphone. Glucuronide formation also occurs primarily in the liver. Since FDA approval of the controlled-release form of oxycodone in 1995, many areas of the U.S. have seen a dramatic increase in the number of deaths in which oxycodone was found to be a contributing factor.
A study of the distribution of the opioids morphine and codeine found that the ratio of codeine to morphine in vitreous humor was similar to that in blood (6). Wyman and Bultman (7) evaluated the distribution of heroin and its metabolites in 25 heroin-related deaths, demonstrating that detection of 6-monoacetylmorphine in vitreous humor was helpful in establishing heroin usage. A study by Antonides et al. (5) compared blood and vitreous fluid concentrations of cocaine and a group of opioids, illustrating no significant matrix effects when vitreous drug concentrations were obtained using blood calibration curves.
In suspected drug-related deaths, forensic toxicology laboratories commonly use immunoassay testing of blood or urine as an initial screen for a panel of drugs of abuse (12, 13) . The DRI Oxycodone Assay (Microgenics, Fremont, CA) utilizes enzyme multiplied immunoassay technique, or EMIT ® , to obtain both qualitative and semiquantitative analysis of oxycodone and oxymorphone. The assay demonstrates 103% cross-reactivity with oxymorphone (14) ; therefore, our investigation excluded cases in which only oxymorphone was detected by gas chromatography-mass spectrometry (GC-MS). The purpose of this study was to evaluate the use of vitreous humor as a screening matrix to be used with the DRI Oxycodone Assay and to assess the extent to which vitreous humor oxycodone concentrations correlate with postmortem blood concentrations as measured by GC-MS.
Materials and Methods

Chemicals and reagents
Methanol, hydrochloric acid, hydroxylamine, monobasic potassium phosphate, and dibasic potassium phosphate were purchased from Mallinckrodt Baker (Phillipsburg, NJ). Ethyl acetate and ammonium hydroxide were purchased from EMD Chemicals (San Diego, CA). Acetone was purchased from Fisher Scientific (Pittsburgh, PA). Trimethylchlorosilane (TMCS) and N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) were purchased from Sigma Aldrich (St. Louis, MO). Oxycodone and oxycodone-d 6 were purchased from Cerilliant (Round Rock, TX). All reagents and solvents were of ACS-grade or better.
Samples
Vitreous humor from both eyes was collected at autopsy, combined, and stored in screw-top polypropylene tubes. Volumes ranged from < 0.5 to 3.0 mL. Blood specimens were collected and stored in polypropylene containers supplemented with sodium fluoride and EDTA (15) . With the exception of four cases, blood obtained at autopsy was collected from the subclavian vein. Two blood samples were collected from the heart, one from the iliac artery and one was an antemortem hospital blood sample. All samples were stored at 4°C until analysis.
Standards
A pool of vitreous humor was prepared from 21 cases that had previously screened negative for drugs and alcohol. The vitreous humor samples were combined and vortex mixed, then centrifuged, and used as a negative control. Aliquots of the negative vitreous humor were spiked with oxycodone to create 10 standards with concentrations ranging from 5 to 4000 ng/mL.
Immunoassay
Blood specimens were prepared using the procedure described by Kroener (16) . Specifically, 1.0-mL aliquots were added to 2.0 mL of acetone in 7-mL glass tubes and vortex mixed. Tubes were then centrifuged for 5 min at 3000 rpm. The organic layer was decanted into 12 × 75-mm glass tubes, acidified, and dried under a stream of nitrogen at 45°C using a TurboVap ® LV Concentration Workstation (Caliper LifeSciences, Hopkinton, MA). The precipitated blood specimens were reconstituted in 0.5 mL of phosphate buffer (0.1 M, pH 6.5) and screened by enzyme immunoassay on a MGC 240 Analyzer (Microgenics, Fremont, CA) using kits purchased from Microgenics. The test panel consisted of amphetamines, barbiturates, benzodiazepines, cocaine metabolite, methadone, opiates, oxycodone, propoxyphene, tricyclic antidepressants, and cannabinoids.
Vitreous humor standards, controls, and case samples in which the blood had screened positive for oxycodone were centrifuged and then analyzed on a MGC 240 using the DRI Oxycodone Assay according to the manufacturer's specifications for urine samples. Calibrators at 100, 300, 500, and 1000 ng/mL were used to provide semiquantitative results. The limit of detection (LOD) of the assay was determined statistically by taking the average blank plus three standard deviations of the mean (17) . All vitreous humor samples that screened positive for oxycodone and were available in a volume of 0.5 mL or more were confirmed and quantitated by GC-MS.
Oxycodone extraction
Samples were prepared for GC-MS analysis by placing 1.0 mL of sample or standard in a 13 × 100-mm glass culture tube. To each tube, 10 µL of 0.01 mg/mL deuterated oxycodone in- ternal standard was added, followed by 1.0 mL phosphate buffer (0.1 M, pH 6) and 0.5 mL 1% hydroxylamine. The tubes were incubated in a water bath for 1 h at 65°C to allow oxime formation (18) . The samples were removed from the water bath, and an additional 2.0 mL of phosphate buffer was added to each tube. The samples were then poured into Trace B tubes (SPEware, San Pedro, CA) that had been conditioned with 2.0 mL ethyl acetate, 2.0 mL methanol, and 1.0 mL distilled water. The Trace B tubes were then washed sequentially with 1.0 mL distilled water, 1.0 mL of 100 mM hydrochloric acid, 1.0 mL methanol, and 1.0 mL ethyl acetate. After drying the columns, samples were eluted into labeled 12 × 75-mm glass culture tubes using 2.0 mL ethyl acetate containing 2% ammonium hydroxide. Eluents were evaporated to dryness under nitrogen gas in a TurboVap at 45°C, reconstituted with 50 µL ethyl acetate, and transferred to autosampler vials. Derivatization was achieved by adding 50 µL MSTFA containing 1% TMCS and incubating at 90°C for 1 h. Vitreous humor volumes of only 0.5 mL were available in nine cases, and only 0.75 mL were available in three cases. Deionized water was used to bring the final volume of each sample to 1.0 mL. These cases are identified in Table I .
GC-MS analysis
GC-MS analysis was performed on an Agilent 6890N GC (Santa Clara, CA) equipped with a split/splitless injector, a 7683 autosampler, and a 5973 mass selective detector. Two microliters of sample were injected in splitless mode onto an HP-5MS capillary column (30 m × 0.25-µm i.d. × 0.50-µm film thickness) with a constant column flow of 1.0 mL/min. The oven temperature was 200°C ramped to 300°C at a rate of 7.5°C/min. The injection port temperature was 260°C, and the transfer line was held at 280°C. Retention times for the oxime/TMS derivatives of oxycodone and its deuterated analogue were 9.48 and 9.44 min, respectively.
Calibrators for whole blood samples consisted of negative serum spiked with oxycodone at concentrations of 10, 50, 500, 1000, and 2000 ng/mL. Calibrators for vitreous humor samples consisted of negative vitreous humor spiked with oxycodone at concentrations of 50, 100, 500, and 1000 ng/mL. Matrixmatched positive controls with oxycodone at 100 and 650 ng/mL were included with each batch. To be accepted, results had to be within ± 20% of the nominal value. The LOD for each matrix was determined by examining ion ratios, retention times, and signal-to-noise ratio. The limit of quantitation (LOQ) was determined by evaluation of these same parameters in addition to quantitation within ± 20% of the target value.
Validation and Results
Immunoassay
Validation of the DRI Oxycodone Assay with postmortem vitreous humor included studies on linearity, LOD, and precision. Specificity data was provided by the manufacturer. The assay was evaluated using the complete range of vitreous humor standards with non-weighted linear regression over a five-day period. The immunoassay responses of the standards with concentrations from 500 to 4000 ng/mL began to plateau as concentration increased (Figure 1) , and the assay was found to be linear from 25 to 500 ng/mL (Figure 2 ). The LOD of the oxycodone-spiked vitreous humor samples was 25 ng/mL.
To determine interday and intraday precision of the immunoassay, vitreous humor standards at concentrations of 50, 200, and 500 ng/mL were analyzed (Table II) . Interday precision, evaluated over a five-day period, ranged from 6.5 to 8.5%, and intraday precision, analyzed in triplicate on three separate days, ranged from 2.4 to 4.1%. Fifty-seven vitreous humor case samples, whose blood precipitates had previously screened positive for oxycodone, were analyzed using the vitreous humor immunoassay curve. Cases that were also positive for other phenanthrene class opiates (codeine, morphine, hydrocodone, hydromorphone) were not included in the study in order to circumvent their possible contribution to the overall immunoassay response. The vitreous humor immunoassay responses were plotted against the blood precipitate responses in order to evaluate the relationship between the two matrices ( Figure 3) . The plot of vitreous humor immunoassay versus blood precipitate immunoassay demonstrated the data to be correlated (r 2 = 0.69, p < 0.01). Each of the vitreous humor samples from cases in which oxycodone had previously been confirmed in the blood also screened positive by immunoassay. No false positives were obtained (n = 20). Figure 4 illustrates the correlation between immunoassay responses for blood precipitates and oxycodone concentration in blood, and Figure 5 shows the correlation between immunoassay responses for vitreous humor and oxycodone concentration in blood.
All vitreous humor samples that were positive for oxycodone and available in a volume of 0.5 mL or more were confirmed by GC-MS.
GC-MS analysis
Validation of the GC-MS oxycodone method for vitreous humor included studies on linearity, LOD, LOQ, and precision. The vitreous humor assay was linear from 50 to 1000 ng/mL (r 2 = 0.99) with an LOD of 10 ng/mL and an LOQ of 50 ng/mL. Interday precision was evaluated over a period of three days at concentrations ranging from 50 to 1000 ng/mL and ranged from 0.9 to 8.1% (n = 3). Interday and intraday precision for vitreous humor spiked at a concentration of 100 ng/mL and measured in triplicate was 5.1% and 1.9%, respectively (Table  III) .
Of the 57 cases included in the immunoassay study, 30 had sufficient vitreous humor (> 0.5 mL) for confirmation and quantitation of oxycodone by GC-MS. The concentration of oxycodone detected in the blood and vitreous humor for each case is shown in Table I . Oxycodone concentrations in blood ranged from 103 to 768 ng/mL and concentrations in vitreous humor ranged from < 50 to 945 ng/mL. Vitreous humor to blood ratios ranged from 0.12 to 3.26 with a mean ratio of 1.16 ± 0.61. In order to determine the relationship between the oxycodone concentrations of the two matrices, vitreous humor concentrations were plotted against the blood concentrations for each case. Figure 6 shows the equation of the regression line, demonstrating the relationship between oxycodone concentrations in the two matrices.
Discussion
Immunoassay and GC-MS methods were developed using vitreous humor as an alternative postmortem matrix for the screening and quantitation of oxycodone. The use of immunoassay to screen for drugs of abuse has been established with urine and various other biological samples (13) . Vogel and Hodnett (19) published a study in 1981 that demonstrated the use of EMIT screening for drugs of abuse in vitreous fluid. Subsequent research has provided further support for the use of vitreous humor as an important postmortem specimen for screening purposes. In a study involving more than 5000 cases, Chronister et al. (20) have recently shown that immunoassay screening of vitreous humor improved opioid detection.
Results presented here indicate that postmortem vitreous humor is a viable alternative screening matrix when used with the Microgenics DRI Oxycodone Assay. The assay was linear from well below the manufacturer's cut-off of 100-500 ng/mL and was able to successfully identify oxycodone in vitreous humor in cases with low oxycodone blood concentrations. The immunoassay responses for vitreous humor samples were similar in magnitude to those commonly seen in blood precipitates from oxycodone-related deaths, illustrating an important benefit of this assay.
As seen in Figure 6 , blood and vitreous humor oxycodone concentrations may demonstrate a positive linear relationship (r 2 = 0.17); however, several cases displayed a large discrepancy between the concentrations in the two matrices. Interestingly, Figure 3 shows that the immunoassay responses are much more highly correlated (r 2 = 0.69).
Oxycodone concentrations in blood and vitreous humor are dependent on numerous factors, including time between administration and death, route of administration, postmortem redistribution, and whether oxycodone is taken in an immediate-or controlled-release form. When the controlled release form of oxycodone is crushed or chewed, oxycodone that was designed for slow dissolution and absorption from the alimentary tract is absorbed quickly, producing higher blood concentrations in a much shorter time (21) . This may account for some variability between concentrations in blood and vitreous humor.
Conclusions
The strong correlation between immunoassay responses in the two matrices indicates that, when used with vitreous humor, the EMIT DRI Oxycodone Assay accurately predicts the presence of oxycodone in blood; however, vitreous humor oxycodone concentrations seem to be unreliable in predicting blood oxycodone concentrations.
